Structure-based drug design of a novel family of PPARγ partial agonists: Virtual screening, X-ray crystallography, and in vitro/in vivo biological activities

Journal of Medicinal Chemistry

Volumn 49, Issue 9, 2006, Pages 2703-2712

  Lu, I Lin ^a,b   Huang, Chien Fu ^a   Peng, Yi Hui ^a   Lin, Ying Ting ^a   Hsieh, Hsing Pang ^a   Chen, Chiung Tong ^a   Lien, Tzu Wen ^a   Lee, Hwei Jen ^b   Mahindroo, Neeraj ^a   Prakash, Ekambaranellore ^a   Yueh, Andrew ^a   Chen, Hsin Yi ^a   Goparaju, Chandra M V ^a   Chen, Xin ^a   Liao, Chun Chen ^c   Chao, Yu Sheng ^a   Hsu, John T A ^a   Wu, Su Ying ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 FLUORO N [1 (4 FLUOROPHENYL) 3 (2 THIENYL) 1H PYRAZOL 5 YL]BENZENESULFONAMIDE; GLITAZONE DERIVATIVE; N [1 (4 FLUOROPHENYL) 3 (2 THIENYL) 1H PYRAZOL 5 YL] 3,5 BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRAZOL 5 YLBENZENESULFONAMIDE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DATA BASE; DRUG DESIGN; DRUG SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; PROTEIN INTERACTION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ADIPOCYTES; ANIMALS; BINDING SITES; CELL DIFFERENTIATION; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIGANDS; MALE; MICE; MODELS, MOLECULAR; PPAR GAMMA; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION, GENETIC;

EID: 33646449916     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051129s     Document Type: Article

References (32)

1. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The Nuclear Receptor Superfamily: The Second Decade. Cell 1995, 83, 835-839.
2. Kliewer, S. A.; Sundseth, S. S.; Jones, S. A.; Brown, P. J.; Wisely, G. B.; Koble, C. S.; Devchand, P.; Wahli, W.; Willson, T. M.; Lenhard, J. M.; Lehmann, J. M. Fatty Acids and Eicosanoids Regulate Gene Expression Through Direct Interactions with Peroxisome Proliferator-Activated Receptors α and γ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4318-4323.
3. Spiegelman, B. M. PPAR-γ: Adipogenic Regulator and Thiazolidinedione Receptor. Diabetes 1998, 47, 507-514.
4. Willson, T. M.; Lambert, M. H.; Kliewer, S. A. Peroxisome Proliferator-Activated Receptor γ and Metabolic Disease. Annu. Rev. Biochem. 2001, 70, 341-367.
5. Berger, J.; Moller, D. E. The Mechanisms of Action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
6. Issemann, I.; Green, S. Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators. Nature 1990, 347, 645-650.
7. Oliver, W. R., Jr.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M. A Selective Peroxisome Proliferator-Activated Receptor δ Agonist Promotes Reverse Cholesterol Transport. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5306-5311.
8. Park, B. H.; Vogelstein, B.; Kinzler, K. W. Genetic Disruption of PPARδ Decreases the Tumorigenicity of Human Colon Cancer Cells. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2598-2603.
9. Basu-Modak, S.; Braissant, O.; Escher, P.; Desvergne, B.; Honegger, P.; Wahli, W. Peroxisome Proliferator-Activated Receptor β Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures. J. Biol. Chem. 1999, 274, 35881-35888.
10. Wang, Y. X.; Zhang, C. L.; Yu, R. T.; Cho, H. K.; Nelson, M. C.; Bayuga-Ocampo, C. R.; Ham, J.; Kang, H.; Evans, R. M. Regulation of Muscle Fiber Type and Running Endurance by PPARδ. PLoS Biol. 2004, 2, E294.
11. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPAR γ). J. Biol Chem. 1995, 270, 12953-12956.
12. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Graver, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T. Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2- phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/ BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities. J. Med. Chem. 2005, 48, 2248-2250.
13. Hegarty, B. D.; Furler, S. M.; Oakes, N. D.; Kraegen, E. W.; Cooney, G. J. Peroxisome Proliferator-Activated Receptor (PPAR) Activation Induces Tissue-Specific Effects on Fatty Acid Uptake and Metabolism In Vivo-A Study Using the Novel PPARα/γ Agonist Tesaglitazar. Endocrinology 2004, 145, 3158-3164.
14. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. J. Med. Chem. 2001, 44, 2675-2678.
15. Doebber, T. W.; Kelly, L. J.; Zhou, G.; Meurer, R.; Biswas, C.; Li, Y.; Wu, M. S.; Ippolito, M. C.; Chao, Y. S.; Wang, P. R.; Wright, S. D.; Moller, D. E.; Berger, J. P. MK-0767, A Novel Dual PPARα/γ Agonist, Displays Robust Antihyperglycemic and Hypolipidemic Activities. Biochem. Biophys. Res. Commun. 2004, 318, 323-328.
16. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective modulator. Mol. Endocrinol. 2003, 17, 662-676.
17. Reifel Miller, A.; Otto, K.; Hawkins, E.; Barr, R.; Bensch, W. R.; Bull, C.; Dana, S.; Klausing, K.; Martin, J.-A.; Rafaeloff-Phail, R.; Rafizadeh-Montrose, C.; Rhodes, G.; Robey, R.; Rojo, I.; Rungta, D.; Snyder, D.; Wilbur, K.; Zhang, T.; Zink, R.; Warshawsky, A.; Brozinick, J. T. A PPARα/γ Dual Agonist with a Unique In Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia. Mol. Endocrinol. 2005, 19, 1593-1605.
18. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand Binding and Co-Activator Assembly of the Peroxisome Proliferator- Activated Receptor-γ. Nature 1998, 395, 137-143.
19. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural Determinants of Ligand Binding Selectivity Between the Peroxisome Proliferator-Activated Receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924.
20. Mahindroo, N.; Huang, C. F.; Peng, Y. H.; Wang, C. C.; Liao, C. C.; Lien, T. W.; Chittimalla, S. K.; Huang, W. J.; Chai, C. H.; Prakash, E.; Chen, C. P.; Hsu, T. A.; Peng, C. H.; Lu, I. L.; Lee, L. H.; Chang, Y. W.; Chen, W. C.; Chou, Y. C.; Chen, C. T.; Goparaju, C. M. V.; Chen, Y. S.; Lan, S. J.; Yu, M. C.; Chen, X.; Chao, Y. S.; Wu, S. Y.; Hsieh, H. P. Novel Indole-Based Peroxisome Proliferator-Activated Receptor Agonists: Design, SAR, Structural Biology, and Biological Activities. J. Med. Chem. 2005, 48, 8194-8208.
21. Mahindroo, N.; Wang, C. C.; Liao, C. C.; Huang, C. F.; Lu, I. L.; Lien, T. W.; Peng, Y. H.; Huang, W. J.; Lin, Y. T.; Hsu, M. C.; Lin, C. H.; Tsai, C. H.; Hsu, J. T. A.; Chen, X.; Lyu, P. C.; Chao, Y. S.; Wu, S. Y.; Hsieh, H. P. IndoI-I-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists: Design, Synthesis, Structural Biology, and Molecular Docking Studies. J. Med. Chem. 2006, 49, 1212-1216.
22. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E.-L.; Bamberg, K. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family. Structure 2001, 9, 699-706.
23. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M. A Peroxisome Proliferator- Activated Receptor γ Ligand Inhibits Adipocyte Differentiation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6102-6106.
24. Gampe, J.; Robert T.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Mol. Cell 2000, 5, 545-555.
25. Iwatsuka, H.; Shino, A.; Suzuoki, Z. General Survey of Diabetic Features of Yellow KK Mice. Endocrinol. Jpn. 1970, 17, 23-35.
26. Elbrecht, A.; Chen, Y.; Adams, A.; Berger, J.; Griffin, P.; Klatt, T.; Zhang, B.; Menke, J.; Zhou, G.; Smith, R. G.; Moller, D. E. L-764406 is a Partial Agonist of Human Peroxisome Proliferator-Activated Receptor γ. The Role of Cys3l3 in Ligand Binding. J. Biol. Chem. 1999, 274, 7913-7922.
27. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E. Novel Peroxisome Proliferator-Activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects. J. Biol. Chem. 1999, 274, 6718-6725.
28. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzvmol. 1997, 276, 307-326.
29. Vagin A, T. A. MOLREP: An Automated Program for Molecular Replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
30. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, G. L.; Warren, T.; Badger, J.; Berard, D.; Kumar, R. A.; Szalma, S.; Yip, P.; Griesinger, C.; Junker, J. Crystallography and NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr. 1998, D54, 905-921.
31. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr. 1997, D53, 240-255.
32. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in these Models. Acta Crystallogr. 1991, A47, 110-119.